New Delhi, February 08, 2018: The organization had posted a benefit after assessment of Rs 194.9 crore for the comparing time of the past monetary, Natco Pharma said in a BSE documenting.
Medication firm Natco Pharma today detailed a 11.54 for each penny ascend in its united benefit after assessment at Rs 217.4 crore for the quarter finished December 2017.
The organization had posted a benefit after assessment of Rs 194.9 crore for the relating time of the past monetary, Natco Pharma said in a BSE recording.
Solidified aggregate incomes of the organization remained at Rs 573.6 crore for the quarter under thought against Rs 685.1 crore in a similar period a year prior.
The organization in a different recording stated, its board has announced second interval profit of Rs 7 on every value offer of Rs 2 for the year 2017-18. Offers of Natco Pharma were exchanging 1.05 for every penny down at Rs 903.70 for every scrip on BSE.
· World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…
By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…
Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Winter weather brings a host…
By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…
Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…
Coimbatore, October 30, 2024: Sri Ramakrishna Hospital’s Neurology experts observes “World Stroke Day” on October…